News

CAR Testimony Informs the Senate on the Necessity for AI Validation in Healthcare 

Since 2018, the CAR has been advocating for legislation for clinician-led oversight of AI infrastructure in Canadian healthcare.  

Today, Dr. Laurent Létourneau-Guillon, dedicated CAR member and Vice-President of the AI Standing Committee, testified before the Senate Committee on Social Affairs, Science and Technology, presenting recommendations for funding the creation of an independent, clinician-led organization to validate clinical AI on Canadian data and to monitor post-deployment. 

“Working with AI is less like working with a tool, and more like working with a new colleague,” he explained, “one we are expected to pay for, validate, supervise, and maintain with the accountability landing on the radiologist. We have learned that a tool that works in a company’s testing does not always work in a hospital.” 

Dr. Létourneau-Guillon’s expert testimony centred on the CAR’s key recommendations: 

  1. Lead national function to validate clinical AI representative of Canadian data and to monitor it after deployment, as part of the AI Missions Program health mission. 
  1. Clinical evidence behind certification. That, for health products, the Canada Trusted AI Certification program relies on independent clinical evaluation that reports performance by patient group and in both official languages, and that requires re-evaluation when a product changes. 
  1. Measure accuracy, not only efficiency. That publicly funded deployments of clinical AI, such as AI scribes, include independent measurement of accuracy and safety, and of their effect on clinicians’ own performance, alongside time saved. 
  1. Equip clinicians. That the federal government work with the provinces and territories, regulatory colleges and specialty societies to support training for clinicians in the safe use and critical appraisal of AI, including automation bias. 
  1. Know what is in use. That Health Canada publish which licensed medical devices use AI, and that the federal government, with the provinces and territories, establish a national inventory of AI tools in clinical use. 


The CAR has presented white papers before the House of Commons in 2018 and 2019 and has included recommendations in pre-budget submissions each year since 2023. Today’s testimony from Dr. Létourneau-Guillon represents a critical step toward advancing health AI validation.  

This invitation to testify underscores the credibility the CAR’s advocacy efforts have built on Parliament Hill. The CAR will continue to monitor the activity and decisions of the Committee.  

Scroll to Top